Showing results (241-250 of 251) with videos related to

Sort By:
Pageof 26
The Laryngoscope|June 15, 2016
Molecular analysis of idiopathic subglottic stenosis for Mycobacterium speciesAlexander Gelbard, Nicolas-George Katsantonis, Masanobu Mizuta, et al.
The Laryngoscope|June 15, 2016
Idiopathic subglottic stenosis is associated with activation of the inflammatory IL-17A/IL-23 axisAlexander Gelbard, Nicolas-George Katsantonis, Masanobu Mizuta, et al.
Molecular Biology of the Cell|April 7, 2017
Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrixArmen H Mekhdjian, FuiBoon Kai, Matthew G Rubashkin, et al.
Kidney International Reports|March 8, 2022
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A Hulton, Jaap W Groothoff, Yaacov Frishberg, et al.
Science (New York, N.Y.)|March 29, 2018
Phenotype risk scores identify patients with unrecognized Mendelian disease patternsLisa Bastarache, Jacob J Hughey, Scott Hebbring, et al.
Haematologica|December 31, 2016
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T Fathi, Seth A Wander, Traci M Blonquist, et al.
The New England Journal of Medicine|March 31, 2021
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1Sander F Garrelfs, Yaacov Frishberg, Sally A Hulton, et al.
Cancer|September 30, 2017
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutationAmir T Fathi, Traci M Blonquist, Daniela Hernandez, et al.
Plos One|June 2, 2015
Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin TherapySara L Van Driest, Tracy L McGregor, Digna R Velez Edwards, et al.
The Lancet. Haematology|December 16, 2019
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trialAndrew M Brunner, Traci M Blonquist, Daniel J DeAngelo, et al.
Pageof 26